S. Semple

发表

Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes.

P. Cullis, N. Maurer, K. Wong, 2001, Biophysical journal.

Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

D. Ribatti, T. Allen, S. Semple, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lipid-based formulations of antisense oligonucleotides for systemic delivery applications.

M. Hope, S. Semple, S. Klimuk, 2000, Methods in enzymology.

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.

P. Cullis, N. Maurer, M. Hope, 2001, Biochimica et biophysica acta.

Rational design of cationic lipids for siRNA delivery

K. G. Rajeev, M. Manoharan, A. Akinc, 2010, Nature Biotechnology.

Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.

K. Edwards, P. Cullis, N. Maurer, 2005, Journal of pharmaceutical sciences.

Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity.

C. Bennett, M. Hope, P. Scherrer, 2000, The Journal of pharmacology and experimental therapeutics.

Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.

P. Cullis, N. Maurer, I. V. Zhigaltsev, 2005, Journal of controlled release : official journal of the Controlled Release Society.

Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid

M. Hope, S. Semple, S. Ansell, 2005, Journal of Pharmacology and Experimental Therapeutics.

Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.

S. Semple, S. Klimuk, J. Dutz, 2004, The Journal of investigative dermatology.

In vivo administration of liposomal vincristine sensitizes drug‐resistant human solid tumors

C. Leonetti, M. Scarsella, G. Zupi, 2004, International journal of cancer.

Influence of cholesterol on the association of plasma proteins with liposomes.

P. Cullis, S. Semple, A. Chonn, 1996, Biochemistry.

Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo.

P. Cullis, S. Semple, A. Chonn, 1991, Biochimica et biophysica acta.

Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.

M. Johnston, K. Edwards, P. Cullis, 2006, Biochimica et biophysica acta.

Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN

P. Cullis, Ying K. Tam, S. Semple, 2007, Cancer Immunology, Immunotherapy.

Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes.

M. Hope, P. Scherrer, S. Semple, 1999, Biochimica et biophysica acta.

Lipid-Based Carriers for the Systemic Delivery of Antisense Drugs

M. Hope, S. Semple, M. Webb, 1999 .

Protein-Membrane Interactions in the Complex Biological Milieu

P. Cullis, S. Semple, A. Chonn, 1994 .

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

M. Manoharan, A. Akinc, P. Cullis, 2019, Nature Nanotechnology.

Abstract 2829: Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1

A. Judge, K. Mcclintock, I. Maclachlan, 2011 .

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

Ying K. Tam, S. Semple, R. Leone, 2022, Pharmaceutics.

High efficiency entrapment of antisense oligonucleotides in liposomes.

D. Stuart, T. Allen, S. Semple, 2004, Methods in enzymology.

Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line

C. Leonetti, G. Zupi, A. Stringaro, 2001, Cancer Gene Therapy.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Jennifer L Marlowe, Violetta Akopian, Priya Karmali, 2017, Nucleic acid therapeutics.

Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.

F. Zunino, R. Supino, C. Lanzi, 2004, Biochemical pharmacology.

Therapeutic integration of c‐myc and bcl‐2 antisense molecules with docetaxel in a preclinical model of hormone‐refractory prostate cancer

C. Leonetti, M. Scarsella, G. Zupi, 2007, The Prostate.

Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.

M. Hope, S. Semple, B. Mui, 2001, The Journal of pharmacology and experimental therapeutics.

Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.

P. Cullis, S. Semple, A. Chonn, 1992, The Journal of biological chemistry.

Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin.

Norbert Maurer, M. Johnston, P. Cullis, 2007, Biochimica et biophysica acta.

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

D. Weissman, M. Stoffel, A. Moor, 2021, Nature Biotechnology.

Influence of dose on liposome clearance: critical role of blood proteins.

P. Cullis, S. Semple, A. Chonn, 1996, Biochimica et biophysica acta.

Liposome-Blood Protein Interactions in Relation to Liposome Clearance

S. Semple, A. Chonn, 1996 .

β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*)

P. Cullis, S. Semple, A. Chonn, 1995, The Journal of Biological Chemistry.

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).

David C. Smith, J. Carpten, W. Liang, 2016 .

A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition.

M. Borad, A. Judge, I. Maclachlan, 2013 .

Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.

M. Gilbert, M. Borad, A. Judge, 2013 .

Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence

C. Leonetti, M. Scarsella, G. Zupi, 2005, Clinical Cancer Research.

Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo

Meghan M. Holdorf, Simin Xu, Ying K. Tam, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo.

P. Cullis, S. Semple, A. Chonn, 1998, Advanced drug delivery reviews.

Therapeutic Integrationof c-myc andbcl-2Antisense MoleculesWithDocetaxelin a PreclinicalModel

C. Leonetti, M. Scarsella, G. Zupi, 2007 .

Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells.

M. Hope, S. Semple, J. Bramson, 2000, Antisense & nucleic acid drug development.